In addition, blockers of EDNRA resensitised cancer cells to paclitaxel-induced apoptosis, as observed in ovarian, prostatic, cervical and nasopharyngeal cancer cell lines [49-51] as well as in primary ovarian and breast cancer [5,52]. Here, EDNRA is linked to breast carcinoma.